![]() The global geriatric population (people aged 65 years or older) worldwide is expected to double over the next three decades. Rising geriatric population globally is increasing the risk of getting a number of diseases including cardiovascular disease, neurological disorders, diabetes, etc. ![]() also have a number of programs that support the development and use of molecular diagnostics for military, public health, and many other purposes. Apart from NIH, The Food and Drug Administration (FDA), The Centers for Disease Control and Prevention (CDC), The Department of Defense (DoD), etc. For instance – The National Institutes of Health (NIH) has the Molecular and Cellular Biology (MCB) program, the National Institute of Allergy and Infectious Diseases (NIAID) Intramural Research Program, the Molecular and Cellular Oncology (MCO) program, and more. are supporting and promoting development in this sector, providing growth opportunities. Rising government initiatives, funding activities, etc.The health organization states that the Global Fund and Joint United Nations Programme on HIV/AIDS – UNAIDS targets to end the HIV epidemic by 2030, and to achieve this, 95% of all HIV-affected people should have a diagnosis. There are over 38 million (33.9–43.8 million) people living with HIV by the end of 2021, according to WHO. the need for accurate and affordable diagnosis also grows substantially. With the growing incidence of STIs such as HIV, HPV, etc. Growing incidence of infectious diseases is one of the primary growth factors over the forecast period.Several dynamics have contributed to this growth, a few are mentioned below– ![]() The molecular diagnostics market has experienced significant growth in recent years. However, the pandemic increased the need of developing diagnostic instruments and diagnostic service centers and hence there was a positive impact on the molecular diagnostics market. The global pandemic Covid-19 impacted almost every industry and shook the market. Molecular diagnostics can provide vital insights about an individual's health status and aid in disease diagnosis, by identifying these biomarkers. These biomarkers can also include chromosomal abnormalities, protein levels, genetic mutations, gene expressions, etc. Molecular diagnostics encompasses a wide range of techniques that allows the detection and analysis of biological markers in the genome and proteome. Want to know more about the market scope? Register Here These two new products are the newest additions to Bio-Rad’s family of negative run controls and matrices in its molecular portfolio, which also includes the Exact Diagnostics Negative Run Control & Exact Diagnostics Bulk Negative (plasma), Exact Diagnostics STI Negative Run Control, Exact Diagnostics Synthetic Negative Run Control and Exact Diagnostics HAI Negative Run Control, the last three having been released late last year.The molecular diagnostics market was estimated at USD 24.68 billion in 2022 and is likely to grow at a CAGR of 4.59% during 2023-2028 to reach USD 32.33 billion in 2028. The Exact Diagnostics Bulk CSF Negative is an independent external quality run control intended to monitor the absence of Anaplasma phagocytophilum, Babesia microti, Bartonella quintana, Borrelia burgdorferi, Ehrlichia chaffeensis, Enterovirus (EV), Herpes Simplex Virus-1 (HSV- 1), Herpes Simplex Virus-2 (HSV-2), and Varicella Zoster Virus (VZV) in various molecular assays. auris), Chlamydia trachomatis (CT), Cytomegalovirus (CMV), John Cunningham virus (JCV), Mycoplasma genitalium (MG), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Zika virus (ZKV) in various molecular assays. The Exact Diagnostics Bulk Urine Negative is intended to be validated as an independent external quality run control to monitor the absence of Adenovirus (ADV), BK virus (BKV), Candida auris ( C. These products may also help in the detection of errors in laboratory testing procedures, including potential contamination events. ![]() Both are matrices designed for spike-in or dilution purposes as well as to be used with molecular assays to monitor their intra- and inter-run performance. Bio-Rad Laboratories has expanded its molecular offering of quality controls with the launch of two new Exact Diagnostics products: Bulk Urine Negative and Bulk CSF Negative.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |